Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 29.46M P/E - EPS this Y -41.70% Ern Qtrly Grth -
Income -8.76M Forward P/E -2.01 EPS next Y -23.50% 50D Avg Chg -18.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.10 EPS next 5Y - 52W High Chg -78.00%
Recommedations 1.70 Quick Ratio 6.55 Shares Outstanding 69.64M 52W Low Chg 14.00%
Insider Own 23.65% ROA -39.74% Shares Float 48.76M Beta 0.77
Inst Own 13.57% ROE -39.00% Shares Shorted/Prior 109.39K/278.17K Price 0.42
Gross Margin - Profit Margin - Avg. Volume 126,072 Target Price 2.75
Oper. Margin - Earnings Date Feb 5 Volume 912,116 Change -7.92%
About Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Medicenna Therapeutics Corp. News
11/17/23 Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
11/14/23 Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
11/13/23 MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11
11/09/23 Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
11/06/23 Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
11/03/23 Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10/27/23 Medicenna Announces Nasdaq Delisting and Cutback of Management Team
10/25/23 Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
10/24/23 Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
10/10/23 Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
10/03/23 Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
04:00 PM Medicenna Announces Results of Annual and Special Meeting of Shareholders
06:00 AM Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
09/26/23 Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?
09/06/23 Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
06:00 AM Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
08/15/23 MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…
08/14/23 Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
08/09/23 Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
08/08/23 Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee